Norris Perne & French’s Galectin Therapeutics GALT Stock Holding History

Norris Perne & French’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-10,500	Closed	-$50K	–	140
2018 Q1	$50K	Sell	10,500 -20,000	-66%	-$93.2K	0.01%	148
2017 Q4	$102K	Hold	30,500	–	–	0.01%	149
2017 Q3	$65K	Hold	30,500	–	–	0.01%	153
2017 Q2	$75K	Hold	30,500	–	–	0.01%	151
2017 Q1	$70K	Hold	30,500	–	–	0.01%	154
2016 Q4	$30K	Hold	30,500	–	–	0.01%	148
2016 Q3	$34K	Hold	30,500	–	–	0.01%	142
2016 Q2	$45K	Hold	30,500	–	–	0.01%	137
2016 Q1	$44K	Hold	30,500	–	–	0.01%	143
2015 Q4	$50K	Hold	30,500	–	–	0.01%	152
2015 Q3	$71K	Hold	30,500	–	–	0.02%	146
2015 Q2	$83K	Hold	30,500	–	–	0.02%	158
2015 Q1	$102K	Hold	30,500	–	–	0.02%	162
2014 Q4	$106K	Buy	30,500 +8,500	+39%	+$37.6K	0.02%	161
2014 Q3	$111K	Buy	+22,000	New	+$171K	0.02%	163

Other funds holding GALT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BCA

Benchmark Capital Advisors New York $101M AUM 0.8% 1-Year Est. Return

EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EGI

EAM Global Investors Solana Beach, California $47.1M AUM 320.45% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Norris Perne & French's GALT Position: Q2 2018 in Review

Norris Perne & French sold out of Galectin Therapeutics (GALT) in Q2 2018, closing a stake of 10,500 shares — an estimated $50K sold.

Norris Perne & French first reported a position in GALT in Q3 2014 and held it in 15 quarters. The position peaked at $111K in Q3 2014. 69 funds tracked by Wall St. Rank hold GALT as of Q2 2018.

Norris Perne & French reported no remaining Galectin Therapeutics position as of Q2 2018 after selling out during the quarter.
Norris Perne & French sold 10,500 Galectin Therapeutics shares in Q2 2018, an estimated $50K.
Norris Perne & French first reported a position in Galectin Therapeutics in Q3 2014 and held it in 15 quarters.
Norris Perne & French's Galectin Therapeutics position peaked at $111K in Q3 2014.
69 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2018.

Based on Norris Perne & French's 13F filing for Q2 2018, filed 24 Jul 2018.